Multi-center transferability of a breath-hold T2 technique for myocardial iron assessment
Journal of Cardiovascular Magnetic Resonance volume 10, Article number: 11 (2008)
Cardiac iron overload is the leading cause of death in thalassemia major and is usually assessed using myocardial T2* measurements. Recently a cardiovascular magnetic resonance (CMR) breath-hold T2 sequence has been developed as a possible alternative. This cardiac T2 technique has good interstudy reproducibility, but its transferability to different centres has not yet been investigated.
Methods and Results
The breath-hold black blood spin echo T2 sequence was installed and validated on 1.5T Siemens MR scanners at 4 different centres across the world. Using this sequence, 5–10 thalassemia patients from each centre were scanned twice locally within a week for local interstudy reproducibility (n = 34) and all were rescanned within one month at the standardization centre in London (intersite reproducibility). The local interstudy reproducibility (coefficient of variance) and mean difference were 4.4% and -0.06 ms. The intersite reproducibility and mean difference between scanners were 5.2% and -0.07 ms.
The breath-hold myocardial T2 technique is transferable between Siemens scanners with good intersite and local interstudy reproducibility. This technique may have value in the diagnosis and management of patients with iron overload conditions such as thalassemia.
The development of transfusion related iron overload in the tissue of myocardium can result in cardiomyopathy [1, 2], and heart failure remains the leading cause of death in beta-thalassemia major (TM) [3, 4]. Myocardial iron measurement is important for assessing the risk of cardiac complications [5, 6], because of the frequency of myocardial siderosis in thalassemia major , and the benefit of tailoring appropriate iron-chelating treatment [7–10].
Cardiovascular magnetic resonance (CMR) provides a non-invasive means of measuring the amount of tissue iron. With CMR, the iron deposition results in shortening of proton relaxation times and both T2 and T2* measurements have been exploited to assess iron overload [7, 11]. Myocardial T2* is fast and simple to implement and has demonstrated good reproducibility in assessing tissue iron content [12–14]. A similar T2 sequence, however, is technically more difficult, and early attempts at implementation were unsatisfactory for myocardial iron measurements due to problems associated with hardware constraints, flow, cardiac motion, and noise [15, 16]. However, T2 is known to vary with myocardial iron [17, 18], and there may be potential advantages of T2 over T2* for the avoidance of problems caused by factors such as shimming and local susceptibility. There is also interest in comparing the myocardial T2* with T2 to discover if additional useful clinical information can be gleaned as to the chemical state of the stored iron. For this purpose, a breath-hold T2 technique has been developed and recently reported . This T2 technique has demonstrated good interstudy reproducibility in London. However, in order to be applicable in healthcare on a wider scale, its transferability between scanners of different centers must be established, but no data on this challenging issue is available to date. We now describe the results of the transfer of this technique to different scanners at 4 different centers in different countries.
MR protocols and study population
The standard center in London used a 1.5T Siemens Sonata scanner. Four other international centers using 1.5T MR scanners were involved in this study. Scanner details were as follows: Center 1, Siemens Sonata (Hong Kong, China); Center 2, Siemens Avanto (Philadelphia, USA); Center 3 Siemens Avanto (Singapore); Center 4, Siemens Symphony Quantum (Izmir, Turkey). The breath-hold black blood T2 sequence developed at London center was installed on each local scanner. The pulse sequence details and methods of T2 calculation have been previously described . In brief, all centers used a four-element cardiac phased array coil to image a single 10 mm mid-ventricular short axis slice at 12 echoes times (ranging from 4.8 ms to 163.2 ms, increment 14.4 ms) with ECG gating. Double inversion recovery pulses were applied to suppress the blood signal and data was acquired every other cardiac cycle. For T2 measurement, a region of interest (ROI) was chosen in the left ventricular septum individually. The mean signal intensity of ROI was measured for each of the images, and the data were plotted against the TEs to form a decay curve. The mono-exponential decay model and the nonlinear curve fitting algorithm were used to fit the curve to obtain T2 measurement. The sequence parameters were kept identical in all centers although small variations would not be expected to affect the T2 measurement.
A total of 34 (mean age 32 ± 9 years) TM patients (10 from Hong Kong, 10 from Singapore, 9 from Philadelphia, 5 from Izmir) were studied. For local interstudy reproducibility, these patients were scanned twice at their local centers within one week. All patients were subsequently rescanned at the standardization center at London (intersite reproducibility) within four weeks of their original scans. These patients had been regularly transfused since early childhood or since the introduction of deferoxamine, and were receiving regular iron chelation. Ethical approval was granted at the standard center and all local centers involved. All patients gave written informed consent.
To quantify both interstudy reproducibility and intersite transferability, the coefficient of variation was calculated (CoV), defined as standard deviation of the differences between the two separate measurements, divided by their mean and expressed as a percentage. Mean differences in T2 between scans are also quoted as a measure of bias. Summary data were expressed with 95% confidence intervals and displayed graphically using scatter plots with line of identity and Bland-Altman plots. Group data were compared using Friedman's test. A p value of < 0.05 was considered statistically significant.
Myocardial T2 measurements (two at each local site and one in London) were 46.4 ± 26.3 ms, 46.4 ± 26.1 ms and 46.3 ± 26.4 ms respectively. Friedman's test showed no significant difference (p = 0.87, n = 34) between these three T2 measurements.
Local interstudy reproducibility
The mean difference was -0.06 ms and the CoV for local interstudy reproducibility was found to be 4.4%. These values are consistent with those of our previous published data . There was no bias between the two measurements (Figure 1).
The mean difference was -0.07 ms and the CoV for intersite reproducibility was found to be 5.2%. These values were similar to those of local interstudy reproducibility mentioned above. This demonstrates good agreement between the standard center scanner and the local scanners at each center and no bias was found (Figure 2).
This study shows that the myocardial T2 values using the recently developed breath-hold T2 sequence agree very well between 1.5 Tesla scanners in different locations around the world. This demonstration of transferability suggests that this technique could be further disseminated worldwide, should its clinical applicability be demonstrated in iron overload conditions. Although the iron deposition affects both T2 and T2* relaxation times, T2 is not affected by extrinsic magnetic field inhomogeneity. Therefore, T2 in principle might provide more accurate measurements. Nevertheless, T2* has substantial clinical validation both in heart and liver suggesting that the potential limitations are more theoretical than real. One potential advantage of T2 might be to perform robust multi-segmental analysis to explore the regional iron distribution, because T2* is currently limited to the septum to avoid susceptibility effects from the anterior and posterior cardiac veins and lungs. This may in due course improve our understanding of how other factors affect T2* across the myocardium. It is possible that different chemical forms of iron in the tissue could have differential effects between T2 and T2*, and measurement of both parameters might be useful if chelators access different forms of iron at different rates. From our studies of both T2* and T2, it is likely that both parameters can assess the tissue iron accurately in the heart using state-of-the-art sequences, and combined analysis may provide more information for patient management. Further research is needed to determine this. One limitation of this study was that only Siemens scanners were involved, and results from other scanners would be useful. There is no substantial barrier to this once the sequence has been adapted by other manufacturers.
To conclude, this study has demonstrated the good intersite reproducibility of the breath-hold T2 technique between 1.5T Siemens MR scanners at different centers across different countries. With widespread application, this T2 technique might yield new insights into the assessment of myocardial iron and may have clinical application possibly in conjunction with T2*.
Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, Anderson LJ, Walker JM, Pennell DJ: Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006, 8: 543-547. 10.1080/10976640600698155.
Maceira AM, Prasad SK, Khan M, Pennell DJ: Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006, 8: 417-526. 10.1080/10976640600572889.
Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR: Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994, 331: 574-578. 10.1056/NEJM199409013310903.
Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A: Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004, 89: 1187-1193.
Tanner MA, Porter JB, Westwood MA, Nair SV, Anderson LJ, Walker JM, Pennell DJ: Myocardial T2* in patients with cardiac failure secondary to iron overload. Blood. 2005, 106 (Suppl): 40B-(Abstract 3838a)
Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD: Myocardial iron loading in transfusion- dependent thalassemia and sickle cell disease. Blood. 2004, 103: 1934-1936. 10.1182/blood-2003-06-1919.
Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron levels and ventricular function in beta thalassemia. Lancet. 2002, 360: 516-520. 10.1016/S0140-6736(02)09740-4.
Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ: Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: A prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004, 127: 348-355. 10.1111/j.1365-2141.2004.05202.x.
Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R: Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006, 107: 3738-3744. 10.1182/blood-2005-07-2948.
Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ: A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007, 115: 1876-1884. 10.1161/CIRCULATIONAHA.106.648790.
Wood JC: Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol. 2007, 14: 183-190. 10.1097/MOH.0b013e3280d2b76b.
Westwood MA, Anderson LJ, Firmin DN, Gatehouse PD, Lorenz CH, Wonke B, Pennell DJ: Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. J Magn Reson Imaging. 2003, 18: 616-620. 10.1002/jmri.10396.
Westwood MA, Firmin DN, Gildo M, Renzo G, Stathis G, Markissia K, Vasili B, Pennell DJ: Intercenter reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging. 2005, 21: 531-538. 10.1007/s10554-005-0651-2.
Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ, Thalassemia International Federation Heart T2* Investigators: Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica. 2006, 91: 1388-1391.
Mavrogeni SI, Gotsis ED, Markussis V, Tsekos N, Politis C, Vretou E, Kermastinos D: T2 relaxation time study of iron overload in b-thalassemia. MAGMA. 1998, 6: 7-12. 10.1007/BF02662506.
Papanikolaou N, Ghiatas A, Kattamis A, Ladis C, Kritikos N, Kattamis C: Non-invasive myocardial iron assessment in thalassaemic patients. T2 relaxometry and magnetization transfer ratio measurements. Acta Radiol. 2000, 41: 348-351. 10.1080/028418500127345442.
Ghugre NR, Enriquez CM, Gonzalez I, Nelson MD, Coates TD, Wood JC: MRI detects myocardial iron in the human heart. Magn Reson Med. 2006, 56: 681-686. 10.1002/mrm.20981.
Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates TD, Pollack H, Moats R: Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005, 112: 535-543. 10.1161/CIRCULATIONAHA.104.504415.
He T, Gatehouse PD, Anderson LJ, Tanner M, Keegan J, Pennell DJ, Firmin DN: Development of a novel optimized breathhold technique for myocardial T2 measurement in thalassemia. J Magn Reson Imaging. 2006, 24: 580-585. 10.1002/jmri.20681.
This work was supported by NIH Grant (R01 DK66084-01) and Novartis Oncology at Basel.
The author(s) declare that they have no competing interests.
About this article
Cite this article
He, T., Kirk, P., Firmin, D.N. et al. Multi-center transferability of a breath-hold T2 technique for myocardial iron assessment. J Cardiovasc Magn Reson 10, 11 (2008). https://doi.org/10.1186/1532-429X-10-11
- Cardiovascular Magnetic Resonance
- Iron Overload
- Myocardial Iron
- Double Inversion Recovery